Professor Melief of ISA Pharmaceuticals awarded 2 prestigious awards at the 37th Society for Immunotherapy of Cancer Annual Meeting

/in

Congratulations to ISA Pharmaceuticals, Chief Scientific Officer & Founder, Professor Dr. Kees Melief who was recently awarded two prestigious awards at this year’s 37th Society for Immunotherapy of Cancer Annual Meeting for his outstanding contribution to the field of cancer immunotherapy and his longstanding commitment and achievements that have the potential to significantly improve patient […]

Read more

LSX and Jefferies – Insights from the busiest week in European biotech 

/in ,

The LSX Inv€$tival Showcase kicked off a hectic week in life sciences on 15 November, with these two key events in the biotech calendar making one of the busiest weeks of the year.  Investors and biotechs saw this as a vital chance to meet up and discuss strategies and potential deals amid these dicey market […]

Read more

Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022

/in ,

For those that were unable to attend on Optimum’s 14th Annual Healthcare Investor Conference, or indeed would like a recap of what was shared on the day, we have been releasing the top takeaways from the panels!   Our first panel of the day, chaired by Stephen Hansen, from BioCentury, saw a panel of blue chip […]

Read more

Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage

/in ,

Dan Mahony and Gareth Powell are long time, successful life sciences and healthcare investors. They are luminaries of the UK and European healthcare ecosystem, who have been investing since the late 1990s and initially worked together at Polar Capital where together they set up the biotech and healthcare investment funds. Gareth is still Head of […]

Read more

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

/in ,

Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]

Read more